Protocol Ledger

NCT05398094 · Phase II · RECRUITING

Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy

Interventional Phase II clinical trial protocol NCT05398094 sponsored by Fundación GECP in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-03-21 Enrollment: 19 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05398094
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)19 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05398094
Protocol FieldVerified Registry Value
NCT IdentifierNCT05398094
Consolidated Lead SponsorFundación GECP
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment19 participants (ESTIMATED)
Registered Start Date2022-03-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05398094
Hospital Research SiteLocationSite Profile
Hospital General Universitario de AlicanteAlicante, SpainOpen Hospital Dossier ->
Hospital Universitari Vall d'HebronBarcelona, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI